Russia have pioneered an innovative herbal anti-cancer medication derived ‘Nima’

This news has been read 1443 times!

A team of researchers from Saratov State Medical University in Russia have pioneered an innovative herbal anti-cancer medication derived from a wild herb widely recognized in certain regions.

Over a decade ago, the researchers embarked on a research journey, culminating in the development of a wild herbaceous plant known as “Avran,” referred to as “Nima” or “the herb of the poor” in Arabic. This plant thrives in various parts of the world. While acknowledging the herb’s toxic properties, the researchers noted its historical use in traditional medicine post boiling. Subsequently, the university secured authorization from the Russian Ministry of Health to initiate a first-phase clinical trial.

Alexander Fedonikov, the Vice President of Saratov University for Scientific Affairs, emphasized that the new medicine derived from the “Avran” herb is unparalleled in the international pharmaceutical index. He clarified that current anti-tumor drugs in the market operate by inhibiting cells, resulting in extensive destruction of cancer cells and severe toxicity to the body.

Fedonikov further elucidated, “Based on the pre-clinical study results, this drug exhibits significantly fewer side effects and is well-tolerated by the body. This extracted medication stands as a groundbreaking achievement and is anticipated to rival the most effective anti-tumor drugs globally.”

The university’s research encompassed ten distinct cancer types, including kidney cancer, bladder cancer, liver cancer, sarcoma, ovarian cancer, among others.

Natalia Polokonova, a professor at Saratov University, shared the promising outcomes from their experiments on laboratory animals. She highlighted that administering the extracted drug led to a 70% reduction in tumor growth rate, a highly encouraging figure. Generally, a drug is deemed effective if it curtails tumor growth by at least 30%.

The university underlined the presence of medicinal plants in their medical resources, affirming their potential and efficacy. Successfully concluding this clinical trial would propel the research to subsequent phases, evaluating its effectiveness. Subsequent phases of clinical trials aim to pave the way for official registration of the drug with the Russian Ministry of Health.

This news has been read 1443 times!